(Q46664514)

24 December 2017

title

Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma (English)

1 reference

24 December 2017

0 references

3

1 reference

24 December 2017

Antonio Palumbo

1

object named as

Antonio Palumbo

1 reference

24 December 2017

author name string

Alessandra Bertola

2

1 reference

24 December 2017

Tommaso Caravita

4

1 reference

24 December 2017

Vincenzo Callea

5

1 reference

24 December 2017

Martina Nunzi

6

1 reference

24 December 2017

Mariella Grasso

7

1 reference

24 December 2017

Patrizia Falco

8

1 reference

24 December 2017

Clotilde Cangialosi

9

1 reference

24 December 2017

Mario Boccadoro

10

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

24 December 2017

published in

Cancer

1 reference

24 December 2017

volume

104

1 reference

24 December 2017

issue

7

1 reference

24 December 2017

page(s)

1428-1433

1 reference

24 December 2017

Thalidomide in multiple myeloma: current status and future prospects

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

Treatment of plasma cell dyscrasias with thalidomide and its derivatives

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

Thalidomide as initial therapy for early-stage myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

IL-8 responsiveness defines a subset of CD8 T cells poised to kill.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21342

7 January 2021

Identifiers

DOI

10.1002/CNCR.21342

1 reference

24 December 2017

1 reference

24 December 2017